Image de couverture de livre

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Shintaro Akiyama, Toshimitsu Fujii
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Letter: Toward Intra‐Class Switching With JAK Inhibitors?
par: Mathieu Uzzan, et autres
Publié: (2025)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
par: Mathieu Uzzan, et autres
Publié: (2025)

Editorial: Evolving Trends in Ulcerative Colitis Management—Insights From the Lothian Cohort
par: Shintaro Akiyama
Publié: (2025)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply
par: Kee Huat Chuah, et autres
Publié: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
par: Yewan Park, et autres
Publié: (2024)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
par: Irene Spinelli, et autres
Publié: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
par: Francisco Idalsoaga, et autres
Publié: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
par: J. M. Schattenberg, et autres
Publié: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
par: Virginia Solitano, et autres
Publié: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
par: Mohamed El‐Kassas, et autres
Publié: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
par: Nina Dominik, et autres
Publié: (2024)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
par: Teresa Seum, et autres
Publié: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
par: Hong‐Li Liu, et autres
Publié: (2026)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
par: Yuki Utakata, et autres
Publié: (2026)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
par: Pinelopi Arvaniti, et autres
Publié: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
par: Alberto Ferrarese, et autres
Publié: (2025)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
par: Chachrit Khunsriraksakul, et autres
Publié: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
par: Juan Macias, et autres
Publié: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
par: Lukas Burghart, et autres
Publié: (2026)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
par: Terry Cheuk‐Fung Yip, et autres
Publié: (2025)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
par: Francisco Idalsoaga, et autres
Publié: (2025)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
par: Sofia Tsitsou, et autres
Publié: (2025)

Letter: Is Enteric Neuropathy Absent in Hypermobility Spectrum Disorders/Hypermobile Ehler–Danlos Syndrome? Authors' Reply
par: Kim W. E. Sweerts, et autres
Publié: (2025)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
par: Ying‐Nan Tsai, et autres
Publié: (2025)

Letter: Methodological Gaps Undermine Conclusions on Electronic Nose Use for Colorectal Cancer Detection—Authors' Reply
par: Milou. L. M. van Riswijk, et autres
Publié: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply
par: Ankit Kumar, et autres
Publié: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
par: Isabel Carbery, et autres
Publié: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
par: Jianhui Zhao, et autres
Publié: (2024)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
par: Christian Labenz, et autres
Publié: (2026)

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease. Authors' Reply
par: Walter W. Chan, et autres
Publié: (2026)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
par: Eunice Yewon Lee, et autres
Publié: (2024)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
par: Hong‐Li Liu, et autres
Publié: (2026)

Letter: Peripheral Eosinophilia Does Not Correlate With Endoscopic and Histological Activity in Paediatric Eosinophilic Oesophagitis. Authors' Reply
par: Pierfrancesco Visaggi, et autres
Publié: (2026)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
par: Isabella Lurje, et autres
Publié: (2025)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
par: Gamal Shiha, et autres
Publié: (2025)

Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply
par: Subin Heo, et autres
Publié: (2025)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
par: Rui Huang, et autres
Publié: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
par: Jiwon Yang, et autres
Publié: (2025)